Swati Gite

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.

P. A. Futreal, I. Wistuba, P. Bhosale, 2022, JAMA oncology.

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.

P. Hwu, Wei-Lien Wang, A. Lazar, 2022, The Lancet. Oncology.

The immune landscape of undifferentiated pleomorphic sarcoma

J. Wargo, E. Keung, K. Wani, 2022, Frontiers in Oncology.

Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies

Mei Jiang, Jaime Rodriguez-Canales, Edwin Roger Parra, 2020, Cancers.

Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases

Young Uk Kim, I. Wistuba, J. Vauthey, 2021, Clinical Cancer Research.

Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state

P. A. Futreal, Hannah C. Beird, K. Hunt, 2021, Acta Neuropathologica.